Post by laurasnowbird on Mar 11, 2005 8:23:56 GMT -5
I know lots of our kids have skin issues, and some may have eczema and use this medication, so I wanted to share this info:
"WASHINGTON, March 10 (Reuters) - Two eczema creams, Elidel and Protopic, should carry a strong advisory about a cancer risk, the U.S. Food and Drug Administration said on Thursday in a warning strongly disputed by the manufacturers.
Research shows the creams are absorbed into the body and may have the potential to cause cancer, the FDA said. It was working on a "black box" warning for the salves -- the strongest warning carried on medicines.
And babies should not be treated with the creams at all, the FDA said.
But Novartis AG , which makes Elidel, disputed the FDA's call for a black box warning and said there would be no change in its label for the time being. Fujisawa Healthcare Inc. which makes Protopic, also said its product is safe.
"FDA has informed Novartis that we will begin discussions about the type of label and the exact wording contained in the label within the next few weeks. There is no change in the label at this time," Novartis said in a statement
And the American Academy of Dermatology, which represents skin specialists, also questioned the move.
"Because these medications are applied to the skin, virtually none of it gets inside the body," dermatologist Dr. Clay thingyerell, president of the academy, said in a statement.
"These are valuable medications, and if used properly, they significantly reduce the debilitating impact of eczema and allow millions of our patients to live normal lives."
The FDA usually negotiates changes in drug labeling with the makers. But the agency has been under fire from consumer groups and Congress, which question whether the agency does enough to monitor the side-effects of medications after they are approved for the market
COMPANY SAYS CREAM SAFE
"Novartis agrees that patients suffering from mild-to-moderate eczema need to be informed about the safe and effective use of Elidel, but we believe a recommendation to add a black box warning to the label is unsubstantiated by clinical evidence and experience in more than five million patients worldwide," the company said.
The FDA said animal studies showed a link with cancer. Tests of whether an agent can cause cancer are done on animals, because it would be unethical to experiment on humans.
"The data showed that the risk of cancer increased as the amount of the drug given increased. The data also included a small number of reports of cancers in children and adults treated with Elidel or Protopic," the FDA said in a statement.
These included seven cases of lymphoma and six skin cancer cases.
In February, members of an FDA advisory panel said they were concerned the companies were aggressively advertising the medicines to treat infants and others with skin problems that the creams are not approved to treat.
Elidel, known generically as pimecrolimus, and Protopic, known generically as tacrolimus, should be used only as directed and only after other eczema treatments have failed to work because of the risk, the FDA said.
"Both products are applied to the skin to control eczema by suppressing the immune system." the agency added. Suppressing the immune system is known to potentially contribute to cancer.
Doctors who prescribe the drugs should remember they should be used only for the shortest time possible, the FDA said.
"Elidel and Protopic are not approved for use in children younger than 2 years old," the FDA added.
Novartis stock closed down 12 cents at $48.70 on the New York Stock Exchange on Thursday. (Additional reporting by Lisa Richwine)"
"WASHINGTON, March 10 (Reuters) - Two eczema creams, Elidel and Protopic, should carry a strong advisory about a cancer risk, the U.S. Food and Drug Administration said on Thursday in a warning strongly disputed by the manufacturers.
Research shows the creams are absorbed into the body and may have the potential to cause cancer, the FDA said. It was working on a "black box" warning for the salves -- the strongest warning carried on medicines.
And babies should not be treated with the creams at all, the FDA said.
But Novartis AG , which makes Elidel, disputed the FDA's call for a black box warning and said there would be no change in its label for the time being. Fujisawa Healthcare Inc. which makes Protopic, also said its product is safe.
"FDA has informed Novartis that we will begin discussions about the type of label and the exact wording contained in the label within the next few weeks. There is no change in the label at this time," Novartis said in a statement
And the American Academy of Dermatology, which represents skin specialists, also questioned the move.
"Because these medications are applied to the skin, virtually none of it gets inside the body," dermatologist Dr. Clay thingyerell, president of the academy, said in a statement.
"These are valuable medications, and if used properly, they significantly reduce the debilitating impact of eczema and allow millions of our patients to live normal lives."
The FDA usually negotiates changes in drug labeling with the makers. But the agency has been under fire from consumer groups and Congress, which question whether the agency does enough to monitor the side-effects of medications after they are approved for the market
COMPANY SAYS CREAM SAFE
"Novartis agrees that patients suffering from mild-to-moderate eczema need to be informed about the safe and effective use of Elidel, but we believe a recommendation to add a black box warning to the label is unsubstantiated by clinical evidence and experience in more than five million patients worldwide," the company said.
The FDA said animal studies showed a link with cancer. Tests of whether an agent can cause cancer are done on animals, because it would be unethical to experiment on humans.
"The data showed that the risk of cancer increased as the amount of the drug given increased. The data also included a small number of reports of cancers in children and adults treated with Elidel or Protopic," the FDA said in a statement.
These included seven cases of lymphoma and six skin cancer cases.
In February, members of an FDA advisory panel said they were concerned the companies were aggressively advertising the medicines to treat infants and others with skin problems that the creams are not approved to treat.
Elidel, known generically as pimecrolimus, and Protopic, known generically as tacrolimus, should be used only as directed and only after other eczema treatments have failed to work because of the risk, the FDA said.
"Both products are applied to the skin to control eczema by suppressing the immune system." the agency added. Suppressing the immune system is known to potentially contribute to cancer.
Doctors who prescribe the drugs should remember they should be used only for the shortest time possible, the FDA said.
"Elidel and Protopic are not approved for use in children younger than 2 years old," the FDA added.
Novartis stock closed down 12 cents at $48.70 on the New York Stock Exchange on Thursday. (Additional reporting by Lisa Richwine)"